Inactive Instrument

Basilea Pharmaceutica AG Share Price Xetra

Equities

PK5

CH0011432447

Biotechnology & Medical Research

Financials

Sales 2024 * 18Cr 20Cr 19Cr 1.68TCr Sales 2025 * 20Cr 22Cr 20Cr 1.83TCr Capitalization 47Cr 52Cr 49Cr 4.35TCr
Net income 2024 * 2.6Cr 2.88Cr 2.68Cr 239.95Cr Net income 2025 * 2.9Cr 3.21Cr 2.99Cr 267.63Cr EV / Sales 2024 * 2.9 x
Net Debt 2024 * 5.68Cr 6.28Cr 5.85Cr 523.84Cr Net Debt 2025 * 1.25Cr 1.38Cr 1.29Cr 115.43Cr EV / Sales 2025 * 2.45 x
P/E ratio 2024 *
18.4 x
P/E ratio 2025 *
16.8 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.61%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 59 01/14/01
Director of Finance/CFO 50 01/09/01
Chief Tech/Sci/R&D Officer 60 01/18/01
Members of the board TitleAgeSince
Director/Board Member 71 27/17/27
Director/Board Member 66 01/22/01
Director/Board Member 69 09/13/09
More insiders
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Calendar
More about the company